Please login to the form below

Not currently logged in
Email:
Password:

Astellas names Linda Friedman as EVP, general counsel

She is due to take up the role on 1 April

Astellas Linda FriedmanAstellas has appointed Linda Friedman as executive vice president, general counsel with responsibility for the company's legal organisation worldwide.

She is set to take up the post from 1 April this year, and will report to Astellas' president and chief executive officer Yoshihiko Hatanaka.

Friedman currently serves as senior vice president and general counsel for Astellas Americas, having first joined Fujisawa in 1993 as a corporate attorney prior to its merger with Yamanouchi.

Since then, Friedman has held positions of increasing responsibility, including senior corporate counsel and vice president for Astellas' US operations and subsequently the Americas region.

She is chair of the board of director at the iBIO Institute, and a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Healthcare Business Women's Association (HBA).

Hatanaka said: “For nearly 24 years, Linda has played a formative role in the evolution of Astellas.

“Linda's role will help develop a new model for our legal team, allowing us to better serve our global and regional business while focusing on the needs of patients worldwide.”

16th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Perspective on biotech
In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating....
Navigating the social media waters in healthcare
...
What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?
Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach...

Infographics